^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastrointestinal Cancer

    1d
    Diagnostic Accuracy of CircRNAs for Detecting Gastrointestinal Cancers: An Updated Meta-analysis. (PubMed, Med J Islam Repub Iran)
    Specific circRNAs (e.g., hsa_circ_0001017, circ-SLC7A5, circ-LDLRAD3) showed promising diagnostic performance. CircRNAs exhibit good diagnostic accuracy for hepatocellular carcinoma (AUC 0.83) and esophageal cancer (AUC 0.81), moderate-to-good accuracy for gastric cancer (AUC 0.79) and pancreatic cancer (AUC 0.78), but limited accuracy for colorectal cancer (AUC 0.68), highlighting their potential as non-invasive biomarkers, particularly for HCC and EC, with further validation needed to enhance clinical utility.
    Retrospective data • Journal
    |
    SLC7A5 (Solute Carrier Family 7 Member 5)
    1d
    Gastric microbiota-mediated immune remodelling in gastric cancer. (PubMed, Gut)
    We conclude by highlighting current challenges and providing future directions for microbiota research in GC. Overall, a deeper understanding of host-microbe interactions can provide promising avenues for precision medicine and the development of microbiota-targeting interventions against GC.
    Review • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    1d
    Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population. (PubMed, Rev Assoc Med Bras (1992))
    The presence of DPYD and UGT1A1 variants is considerable among Brazilian gastrointestinal cancer patients, reinforcing the promising use of pre-therapeutic genetic tests for irinotecan and fluoropyrimidines to avoid severe toxicities related to treatment. Genetic panels for these variants must be continuously updated and adapted for population-specific characteristics.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    irinotecan
    2d
    Optimizing Integrative Oncology Approaches to Address Chemotherapy-induced Peripheral Neuropathy in Gastrointestinal (GI) Cancer Patients: A SMART Pilot Study (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    2d
    Screening of Biomarkers for Postoperative Cognitive Dysfunction in Patients with Metabolic Syndrome (ChiCTR2600121575)
    P=N/A, N=80, The First Hospital of Lanzhou University; The First Hospital of Lanzhou University
    New trial
    2d
    Research on Knowledge-Guided Information Modeling and Application of Fluid Therapy (ChiCTR2600121380)
    P=N/A, N=2988, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial
    2d
    A Comparative Study on the Effects of Super Minimally Invasive Surgery and Organ-Resection Surgery for Gastric Tumors on Brain Function (ChiCTR2600121338)
    P=N/A, N=40, General Hospital of the Chinese People's Liberation Army; General Hospital of the Chinese People's Liberation Army
    New trial
    |
    GAST (Gastrin 2) • LEP (Leptin)
    2d
    Development and Validation of a Model to Predict the Risk of Intraoperative and Postoperative Hypoglycemia in Patients Undergoing Surgery for Gastrointestinal Tumors (ChiCTR2600121162)
    P=N/A, N=1500, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New trial
    2d
    Real-world study of Iparomlimab and Tuvonralimab (QL1706)-based therapy for gastrointestinal tumors (ChiCTR2600121037)
    P=N/A, N=500, Nantong Tumor Hospital; Nantong Tumor Hospital
    New trial • Real-world evidence
    |
    Qibeian (iparomlimab/tuvonralimab)
    2d
    Clinical study on the relationship between metabolites and pan cancer (ChiCTR2600120255)
    P=N/A, N=100, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New trial • Pan tumor
    2d
    Observational Study of Fosrolapitant and Palonosetron Hydrochloride for Injection for the Prevention of Treatment-Related Nausea and Vomiting in Cancer Patients (ChiCTR2600120263)
    P=N/A, N=300, Shanghai General Hospital; Shanghai General Hospital
    New trial
    2d
    The Effect of a Multi-stage Optimisation Strategy on Perioperative Thirst and Dry Mouth in Gastrointestinal Cancer Patients: A Quasi-experimental Study (ChiCTR2600120065)
    P=N/A, N=132, Completed, Second Affiliated Hospital of Air Force Medical University; Second Affiliated Hospital of Air Force Medical University
    New trial